Last updated: February 27, 2026
What is the Commercial Status of NDC 70677-1221?
NDC 70677-1221 refers to Herceptin (trastuzumab), a monoclonal antibody used in targeted therapy for HER2-positive breast and gastric cancers. It is marketed primarily by Genentech, a Roche subsidiary.
Market Size and Patient Population
Global and U.S. Market
The size of the HER2-positive breast cancer segment influences Herceptin's market penetration. The estimated number of new HER2-positive breast cancer cases annually:
| Region |
Estimated New Cases (2022) |
Percentage HER2-positive |
Estimated Patients Eligible for Herceptin |
| U.S. |
287,000 |
15-20% |
43,000 – 57,400 |
| Global |
2.3 million |
15-20% |
345,000 – 460,000 |
In the U.S., approximately 45,000 patients receive Herceptin annually, accounting for the approved indications: early-stage and metastatic HER2-positive breast cancer.
Competitive Landscape
Herceptin faces competition from biosimilars and other targeted agents. biosimilar versions launched from 2019 have gained market share, reducing pricing power.
Pricing Benchmarks and Trends
Current Price Points
The wholesale acquisition cost (WAC) for Herceptin in the U.S. as of 2023:
| Formulation |
Dose |
WAC per Vial |
Typical Dose |
Total Treatment Cost (Approximate) |
| 440 mg/10 mL (single-use vial) |
600 mg (monthly dose) |
$2,300 |
$13,800/month |
$138,000 over 10 months |
| Biosimilar (e.g., Ogivri) |
Same |
20-30% lower |
Similar |
20-30% less |
Price Trends (2019-2023)
- Pre-biosimilar era (2019): WAC ~$2,300 per 440-mg vial.
- Post-biosimilar entry (2020+): Prices declined approximately 20-30% due to biosimilar competition.
- Market shifts: Price reductions led to increased access but impacted margins.
Policy and Reimbursement Factors
- CMS reimbursement rates favor biosimilars.
- Insurance providers increasingly favor cost-effective biosimilars, pressuring branded drug prices.
Revenue Projections
Current Revenue (2022-2023)
- Estimated U.S. sales: ~$4 billion annually.
- Remaining market share with the originator: roughly 70% as biosimilars expand their footprint.
Future Revenue Outlook (2025-2030)
Pricing pressures from biosimilars and competitive agents forecast a decline:
| Year |
Estimated Revenue (U.S.) |
Notes |
| 2025 |
~$2.5 billion |
Biosimilar market expansion, price erosion continues |
| 2030 |
~$1.8 billion |
Further biosimilar adoption, potential new indications |
Key Drivers for Revenue Changes:
- Biosimilar penetration rate reaching 50-60% by 2025.
- New approvals for earlier-stage HER2-positive indications.
- Enhanced competition from novel targeted agents (e.g., Tucatinib).
Price Projection Summary
| Year |
Estimated WAC per 440 mg Vial |
Comments |
| 2023 |
~$2,300 |
Current retail price, biosimilar competition ongoing |
| 2025 |
~$1,600 |
Expected reduction driven by biosimilars and negotiations |
| 2030 |
~$1,200 |
Potential further price reductions, stricter reimbursement policies |
Risks and Uncertainties
- Regulatory approvals of new indications or biosimilars.
- Changes in healthcare policy impacting reimbursement.
- Development of oral or alternative therapies reducing treatment volume.
Key Takeaways
- Herceptin (NDC 70677-1221) remains a high-value oncology drug with a global sales forecast declining due to biosimilar entry.
- Dynamic biosimilar competition has led to roughly 20-30% price erosion since 2019.
- Revenue projections suggest significant decline in market size and pricing by 2030.
- The primary growth driver is the expansion into new indications and earlier-stage treatment settings.
- Market share shifts favor biosimilars, impacting incumbent pricing and profitability.
FAQs
Q1: How much has the price of Herceptin decreased since biosimilars entered the market?
A: Prices have declined approximately 20-30% since biosimilar versions launched in 2019.
Q2: What is the current market share of biosimilars for Herceptin in the U.S.?
A: Biosimilars have gained an estimated 30-40% market share as of 2023.
Q3: What factors could alter the revenue projections for Herceptin?
A: Regulatory approvals of new indications, patent litigations, or faster adoption of alternative therapies could impact revenues.
Q4: Are there emerging therapies that could further challenge Herceptin’s market?
A: Yes, agents such as Tucatinib and ADCs targeting HER2 may further cannibalize Herceptin’s market share.
Q5: How do policy changes influence Herceptin pricing?
A: Government reimbursement trends favor biosimilars, leading to increased pressure on prices and revenue.
References
- IQVIA. (2022). National Sales Dashboard.
- SSR Health. (2022). U.S. Biologic and Biosimilar Market Data.
- FDA. (2020). Biosimilar Approvals.
- MedAd News. (2023). Biosimilars: Market Trends and Pricing.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement Policies for Oncology Drugs.
